Literature DB >> 25997473

Frequency of TERT Promoter Mutations in Prostate Cancer.

Robert Stoehr1, Helge Taubert, Ulrike Zinnall, Johannes Giedl, Nadine T Gaisa, Maximilian Burger, Petra Ruemmele, Carolyn D Hurst, Margaret A Knowles, Bernd Wullich, Arndt Hartmann.   

Abstract

OBJECTIVE: Recently, recurrent mutations within the core promoter of the human telomerase reverse transcriptase (TERT) gene generating consensus binding sites for ETS transcription factor family members were described in melanomas and other malignancies (e.g. bladder cancer, hepatocellular carcinoma). These mutations were discussed as early drivers for malignant transformation. In prostate cancer (PrCa) TERT expression has been associated with a poor prognosis and higher risk for disease recurrence. The underlying mechanisms for high TERT expression in PrCa have still not been clarified. To date, data on TERT promoter mutation analysis in PrCa are sparse. Therefore, we performed sequence analysis of the core promoter region of the TERT gene in an unselected cohort of prostate tumors.
METHODS: Sections from 167 formalin-fixed, paraffin-embedded and cryopreserved prostate tumors were microdissected and used for DNA isolation. The mutation hotspot region within the TERT core promoter (-260 to +60) was analyzed by direct Sanger sequencing or SNaPshot analysis.
RESULTS: All cases were analyzed successfully. Mutations within the core promoter of the TERT gene were not detected in any of the cases with all tumors exhibiting a wild-type sequence.
CONCLUSION: TERT core promoter mutations reported from several other malignancies were not detected in our unselected cohort of PrCa. These data indicate that alterations within the core promoter of the TERT gene do not play an important role in prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25997473     DOI: 10.1159/000381903

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  17 in total

1.  TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma.

Authors:  Rahul Mannan; Alexander S Taylor; Daniel E Spratt; Arul M Chinnaiyan; Jeffrey S Montgomery; Noah A Brown; Rohit Mehra
Journal:  Pathol Res Pract       Date:  2019-09-21       Impact factor: 3.250

2.  TERT promoter mutations in melanoma survival.

Authors:  Eduardo Nagore; Barbara Heidenreich; Sívaramakrishna Rachakonda; Zaida Garcia-Casado; Celia Requena; Virtudes Soriano; Christoph Frank; Victor Traves; Esther Quecedo; Josefa Sanjuan-Gimenez; Kari Hemminki; Maria Teresa Landi; Rajiv Kumar
Journal:  Int J Cancer       Date:  2016-03-02       Impact factor: 7.396

3.  DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.

Authors:  Donghyun D Lee; Ricardo Leão; Martin Komosa; Marco Gallo; Cindy H Zhang; Tatiana Lipman; Marc Remke; Abolfazl Heidari; Nuno Miguel Nunes; Joana D Apolónio; Aryeh J Price; Ramon Andrade De Mello; João S Dias; David Huntsman; Thomas Hermanns; Peter J Wild; Robert Vanner; Gelareh Zadeh; Jason Karamchandani; Sunit Das; Michael D Taylor; Cynthia E Hawkins; Jonathan D Wasserman; Arnaldo Figueiredo; Robert J Hamilton; Mark D Minden; Khalida Wani; Bill Diplas; Hai Yan; Kenneth Aldape; Mohammad R Akbari; Arnavaz Danesh; Trevor J Pugh; Peter B Dirks; Pedro Castelo-Branco; Uri Tabori
Journal:  J Clin Invest       Date:  2018-12-03       Impact factor: 14.808

4.  Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas.

Authors:  Simone Bertz; Armin Ensser; Robert Stoehr; Markus Eckstein; Hendrik Apel; Doris Mayr; Maike Buettner-Herold; Nadine Therese Gaisa; Eva Compérat; Bernd Wullich; Arndt Hartmann; Antje Knöll
Journal:  Mod Pathol       Date:  2020-02-11       Impact factor: 7.842

Review 5.  Telomeres and telomerase in prostate cancer development and therapy.

Authors:  Mindy Kim Graham; Alan Meeker
Journal:  Nat Rev Urol       Date:  2017-07-04       Impact factor: 14.432

Review 6.  Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.

Authors:  Mohammad A Jafri; Shakeel A Ansari; Mohammed H Alqahtani; Jerry W Shay
Journal:  Genome Med       Date:  2016-06-20       Impact factor: 11.117

Review 7.  Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications.

Authors:  Tiantian Liu; Xiaotian Yuan; Dawei Xu
Journal:  Genes (Basel)       Date:  2016-07-18       Impact factor: 4.096

8.  TERT Core Promotor Mutations in Early-Onset Bladder Cancer.

Authors:  Johannes Giedl; Anja Rogler; Andreas Wild; Marc-Oliver Riener; Thomas Filbeck; Maximilian Burger; Petra Rümmele; Carolyn Hurst; Margaret Knowles; Arndt Hartmann; Ulrike Zinnall; Robert Stoehr
Journal:  J Cancer       Date:  2016-05-07       Impact factor: 4.207

9.  A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.

Authors:  Pedro Castelo-Branco; Ricardo Leão; Tatiana Lipman; Brittany Campbell; Donghyun Lee; Aryeh Price; Cindy Zhang; Abolfazl Heidari; Derek Stephens; Stefan Boerno; Hugo Coelho; Ana Gomes; Celia Domingos; Joana D Apolonio; Georg Schäfer; Robert G Bristow; Michal R Schweiger; Robert Hamilton; Alexandre Zlotta; Arnaldo Figueiredo; Helmut Klocker; Holger Sültmann; Uri Tabori
Journal:  Oncotarget       Date:  2016-09-06

10.  Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.

Authors:  Kunal C Kadakia; Scott A Tomlins; Saagar K Sanghvi; Andi K Cani; Kei Omata; Daniel H Hovelson; Chia-Jen Liu; Kathleen A Cooney
Journal:  J Hematol Oncol       Date:  2015-10-06       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.